Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs.

ABSTRACT:

Objective

Epidermal growth factor receptor (EGFR) specific mutations have been known to improve survival of patients with non-small-cell lung carcinoma (NSCLC). However, whether there are any changes of EGFR mutations after targeted therapy and its clinical significance is unclear. This study was to identify the status of EGFR mutations after targeted therapy and predict the prognostic significance for NSCLC patients.

Methods

A total of forty-five (45) NSCLC patients who received EGFR-TKI therapy were enrolled. We identified the changes of EGFR mutations in plasma ctDNA by Amplification Refractory Mutation System (ARMS) PCR technology.

Results

In the 45 cases of NSCLC with EGFR mutations, the EGFR mutation status changed in 26 cases, in which, 12 cases (26.7%) from po

SUBMITTER: Zhang C 

PROVIDER: S-EPMC5363800 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature